Lori Capone

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis

Myeloid-derived suppressor cells coming of age

Lenalidomide downregulates the cell survival factor, interferon regulatory factor‐4, providing a potential mechanistic link for predicting response

Molecular mechanisms of cereblon-based drugs

Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma

PLGA-based nanoparticles: An overview of biomedical applications

Macrophages in immunoregulation and therapeutics

Dissecting fibrosis: therapeutic insights from the small-molecule toolbox

Psoriasis

Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis

Continuous‐Flow Technology—A Tool for the Safe Manufacturing of Active Pharmaceutical Ingredients

Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma

PROTAC targeted protein degraders: the past is prologue

Hidradenitis suppurativa

Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial

Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position

Postallograft lenalidomide induces strong NK cell–mediated antimyeloma activity and risk for T cell–mediated GvHD: Results from a phase I/II dose-finding study

The Effects of Arterial Blood Pressure Reduction on Endocan and Soluble Endothelial Cell Adhesion Molecules (CAMs) and CAMs Ligands Expression in Hypertensive Patients on Ca-Channel Blocker Therapy

Nitric oxide/cGMP pathway signaling actively down-regulates α4β1-integrin affinity: an unexpected mechanism for inducing cell de-adhesion

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients

Biological Activity of Lenalidomide and Its Underlying Therapeutic Effects in Multiple Myeloma

Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group, dose‐comparison study

Peptidic degron for IMiD-induced degradation of heterologous proteins

Psoriasis Pathogenesis and Treatment

Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies

Radical “On Water” Addition to the C═N Bond of Hydrazones: A Synthesis of Isoindolinone Derivatives

Modulation of immune responses through direct activation of Toll-like receptors to T cells

A Scalable Procedure for Light-Induced Benzylic Brominations in Continuous Flow

Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome

Multiple Myeloma

Chemistry Takes a Bath: Reactions in Aqueous Media

Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration

Apremilast, a cAMP phosphodiesterase‐4 inhibitor, demonstrates anti‐inflammatory activity in vitro and in a model of psoriasis

Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study

Isosteric analogs of lenalidomide and pomalidomide: Synthesis and biological activity

Anti-Proliferative and Apoptotic Activity of Lenalidomide in Combination with Rituximab in Follicular Lymphoma: An in Vitro and Ex Vivo Analysis in Follicular Lymphoma Cells.

Aiolos Overexpression in Systemic Lupus Erythematosus B Cell Subtypes and BAFF-Induced Memory B Cell Differentiation Are Reduced by CC-220 Modulation of Cereblon Activity

Dexamethasone Synergizes with Lenalidomide to Inhibit Multiple Myeloma Tumor Growth, But Reduces Lenalidomide-Induced Immunomodulation of T and NK Cell Function

Opposing Effects of Dexamethasone on Lenalidomide Activity in Multiple Myeloma: Additive/Synergistic Effects on Anti-Proliferative Activity on Myeloma Cells and Antagonistic Effects on Immune Function